Eli Lilly ($LLY): Oral GLP-1 results strengthens the Obesity thesis

Introduction

Few companies have managed to capture investor imagination in recent years the way Eli Lilly has. Powered by Mounjaro and Zepbound, Lilly has become the leader in the obesity megatrend. The latest data from the Phase 3 ATTAIN-2 trial of orforglipron, its oral GLP-1 candidate, is another milestone in this journey. It reinforces the company’s …